Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-906 in Japanese Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs Trazpiroben (Primary)
- Indications Gastroparesis
- Focus Adverse reactions
- Sponsors Takeda
- 01 Jun 2022 Results assessing safety, tolerability and disposition of Trazpiroben and findings were compared from a prior US trial in healthy individuals published in the Clinical Pharmacology in Drug Development
- 23 Sep 2020 Results of phase 1 single and multiple ascending dose studies assessing similarity in pharmacokinetics and pharmacodynamics of TAK-906, in Healthy Japanese and Non Japanese Participants, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 19 Oct 2017 Status changed from recruiting to completed.